5 completed. 3 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 3 |
| Phase 2 | 2 | Completed 2 |
Follow Allovectin-7: new trials by email Literature Review of Allovectin-7 trials Research Report on Allovectin-7
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 3 Pivotal Trial Comparing Allovectin-7® Alone vs Chemotherapy Alone in Patients With Stage 3 or Stage 4 Melanoma Allovectin-7®, Dacarbazine (DTIC), Temozolomide (TMZ) - Metastatic Melanoma | Phase 3 | Completed | Vical | 390 | 2006-10-01 | 2013-09-13 |
| Phase II Trial of Allovectin-7® for Metastatic Melanoma Allovectin-7® - Melanoma, Metastatic Melanoma | Phase 2 | Completed | Vical | 133 | 2001-02-01 | 2011-07-07 |
| Gene Therapy in Treating Patients With Stage III or Stage IV Melanoma allovectin-7 - Stage IV Melanoma, Stage III Melanoma | Phase 2 | Completed | Vical | 78 | 1998-08-01 | 2011-07-07 |
| Chemotherapy With or Without Immunotherapy in Treating Patients With Stage III or Stage IV Melanoma allovectin-7, allovectin-7/dacarbazine, dacarbazine - Stage IV Melanoma, Stage III Melanoma | Phase 3 | Completed | Vical | 1998-07-01 | 2008-07-25 | |
| Phase II Trial of Allovectin-7® for Head and Neck Cancer Allovectin-7® - Head and Neck Cancer, Squamous Cell Carcinoma of the Oral Cavity or Oropharynx | Phase 3 | Completed | Vical | 2008-06-24 |
Melanoma (4) · Neoplasms (4) · Skin Neoplasms (3) · Neoplasm Metastasis (2) · Carcinoma (1) · Head and Neck Neoplasms (1) · Laryngeal Diseases (1) · Lip Neoplasms (1) · Otorhinolaryngologic Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1) · Tongue Neoplasms (1)
Vical (5)
United States (5) · Belgium (1) · Brazil (1) · Canada (1) · France (1) · Germany (1) · Israel (1) · Italy (1) · Netherlands (1) · Poland (1) · Russia (1) · Spain (1) · Switzerland (1) · Turkey (Türkiye) (1)
Cherie Smith (1) · Jennifer Fernandez (1) · Linda Strause, PhD (1)